Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inviro Medical Devices CEO to retire
Tony Holler, Inviro chairman of the board and former CEO of ID Biomedical, will serve as the company’s interim CEO until a permanent replacement is named. Mr Clarke
Tony Holler, Inviro chairman of the board and former CEO of ID Biomedical, will serve as the company’s interim CEO until a permanent replacement is named. Mr Clarke
Dr Carter joins VLST from Seattle Genetics, where he led antibody technologies since 2003 including as vice president, since 2004. Prior to that, Dr Carter was director of
Piramal Healthcare will pay cash consideration of E7.7 million for the transaction. The transaction includes the brand rights, contracts, registrations, dossiers and know-how relating to Haemaccel and associated
FDC’s Ciprofloxacin Ophthalmic Solution is a broad spectrum antibiotic used for occular surface infections. The company has recently received approval for Timolol maleate ophthalmic solution. Another abbreviated new
The acquisition was completed by way of an asset purchase under which Natus acquired the assets of the neurology division of Schwarzer including all shares in MMT Muenchner
The negotiated contract is valued at approximately $359,000 per year for a total of approximately $1.8 million over the life of the contract. After the initial one year
The new patent is related to treatment of patients in need of bone marrow or stem cell transplantation. This patent is based on evidence that treatment with SDF-1
The Phase IIb trial was designed to explore the safety, tolerability and efficacy of Spheramine, the company’s novel cell-based therapy for the potential treatment of moderate to advanced
The Phase II clinical trial in Israel is being conducted simultaneously with the Phase II clinical trial in the US, which commenced on March 27, 2008 and is
As part of the transaction, Gaymar has also acquired a new license agreement that gives the company exclusive worldwide rights to new gel technologies, offering promise for potential